GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (MEX:AGIO) » Definitions » Cyclically Adjusted Revenue per Share

Agios Pharmaceuticals (MEX:AGIO) Cyclically Adjusted Revenue per Share : MXN12.27 (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Agios Pharmaceuticals Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Agios Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2024 was MXN2.779. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN12.27 for the trailing ten years ended in Jun. 2024.

During the past 12 months, Agios Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was -4.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-09-26), Agios Pharmaceuticals's current stock price is MXN397.93. Agios Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 was MXN12.27. Agios Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 32.43.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Agios Pharmaceuticals was 36.86. The lowest was 12.39. And the median was 19.15.


Agios Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Agios Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Agios Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 29.38 24.12

Agios Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.21 23.92 24.12 18.37 12.27

Competitive Comparison of Agios Pharmaceuticals's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Agios Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agios Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Agios Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Agios Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=2.779/132.5538*132.5538
=2.779

Current CPI (Jun. 2024) = 132.5538.

Agios Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 12.439 100.428 16.418
201412 6.144 99.070 8.221
201503 14.011 99.621 18.643
201506 5.556 100.684 7.315
201509 2.469 100.392 3.260
201512 2.839 99.792 3.771
201603 14.221 100.470 18.762
201606 3.400 101.688 4.432
201609 4.507 101.861 5.865
201612 11.083 101.863 14.422
201703 4.680 102.862 6.031
201706 4.387 103.349 5.627
201709 4.254 104.136 5.415
201712 3.944 104.011 5.026
201803 2.858 105.290 3.598
201806 13.758 106.317 17.153
201809 4.899 106.507 6.097
201812 10.126 105.998 12.663
201903 10.031 107.251 12.398
201906 8.577 108.070 10.520
201909 8.737 108.329 10.691
201912 -24.306 108.420 -29.716
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 0.000 117.630 0.000
202203 0.304 121.301 0.332
202206 2.049 125.017 2.173
202209 1.290 125.227 1.365
202212 1.529 125.222 1.619
202303 1.829 127.348 1.904
202306 2.069 128.729 2.130
202309 2.310 129.860 2.358
202312 2.156 129.419 2.208
202403 2.410 131.776 2.424
202406 2.779 132.554 2.779

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Agios Pharmaceuticals  (MEX:AGIO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Agios Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=397.93/12.27
=32.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Agios Pharmaceuticals was 36.86. The lowest was 12.39. And the median was 19.15.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Agios Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Agios Pharmaceuticals Business Description

Industry
Traded in Other Exchanges
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Agios Pharmaceuticals Headlines

From GuruFocus